Navigation Links
Metabolix Announces Third Quarter 2013 Financial Results
Date:11/5/2013

CAMBRIDGE, Mass., Nov. 5, 2013 /PRNewswire/ -- Metabolix, Inc. (NASDAQ: MBLX), an innovation-driven performance biomaterials company delivering sustainable solutions to the plastics, chemicals and energy industries, today reported financial results for the three months ended September 30, 2013.

"In the third quarter, we continued to make progress in the execution of our commercial strategy and in developing high value applications for our PHA products," said Richard P. Eno, President and Chief Executive Officer. 

"In biopolymers, we continue to develop markets for compostable film and bags, for performance additives and for applications requiring functional biodegradation. In October, we launched I6003rp, a new polymeric modifier for recycled PVC, and presented data on the product at a technical conference. In September, we broadened our suite of film resins with the launch of Mvera B5010, a new certified compostable resin for film and bag applications. Mvera B5010 is a product developed in collaboration with Samsung Fine Chemicals. We featured these products plus I6001, another PHA performance additive for flexible and semi-rigid PVC, at the recent K 2013 International Trade Fair held in Germany last month." 

Mr. Eno continued, "Engineering work is ongoing aimed at establishing commercial PHA manufacturing, and in parallel, we continue to advance our formulation expertise, which allows us to extend our inventory and optimize products to meet market needs."  

"In our chemicals platform, we recently achieved three key technical milestones in our program.
We demonstrated a process to efficiently recover ultra-high purity bio-GBL from fermentation broth.  We also showed that our fermentation process and P4HB technology can be adapted to produce deuterated bio-GBL. In addition, we demonstrated the robust nature of our microbial strains for production of biobased chemicals based on the successful conversion of second generation, or cellulosic, sugars to PHA precursors for C3 (bio-acrylic) and C4 chemicals," added Mr. Eno.THIRD QUARTER AND NINE MONTHS 2013 FINANCIAL OVERVIEWMetabolix manages its finances with an emphasis on cash flow. The Company has maintained this focus and ended the third quarter with $25.7 million in unrestricted cash and investments. The Company's net cash used for operating activities during the third quarter of 2013 was $5.9 million, which decreased from the net cash used of $6.3 million for the comparable quarter in 2012. Metabolix continues to have no debt.

Total revenue in the third quarter of 2013 was $0.9 million, compared to $0.7 million for the comparable quarter in 2012. The third quarter revenue consisted primarily of revenue from work performed on government research grants and product sales. Grant revenue of $0.6 million remained consistent over the same quarter of 2012, primarily as a result of work performed on the Company's $6.0 million DOE grant. Biopolymer product orders of $0.2 million were shipped and billed during the Company's third quarter of 2013. Revenue recognition was deferred for the majority of these shipments in accordance with the Company's policy to defer product revenue for the greater of 60 days or until receipt of customer payment. During the third quarter, $0.3 million in product revenue was recognized, which is a $0.2 million increase over the comparable quarter of 2012, primarily attributable to the Company's implementation of the current product revenue recognition policy during the third quarter of 2012 which resulted in limited revenue recognized during Q3 2012.

Cost of product revenue recognized was $0.5 million during the quarter ended September 30, 2013, compared to $0.3 million for the comparable period in 2012. The increase of $0.2 million was primarily attributable to an increase in associated product revenue recognized.

Research and development expenses were $4.6 million for the third quarter of 2013, compared to $4.9 million for the same period in 2012. The decrease of $0.3 million is primarily due to a $0.1 million reduction in employee compensation and benefits and a decrease in depreciation expense of $0.1 million. Selling, general and administrative expenses were $3.0 million for the third quarter of 2013 compared to $3.2 million for the comparable quarter in 2012. The decrease of $0.2 million is primarily attributable to a $0.2 million reduction in professional fees related to patent activities.

The Company reported a net loss of $7.3 million, or $0.21 per share, for the third quarter of 2013, as compared to a net loss of $7.7 million, or $0.23 per share, for the third quarter of 2012.

Revenue for the nine months ended September 30, 2013 was $4.5 million, compared to $40.9 million in the same period of 2012. The year-over-year decrease was primarily related to $38.9 million in deferred revenue that was recognized in 2012 as a result of the termination of the Telles joint venture in early 2012. Product revenue, grant revenue and research and development revenue increased by $1.4 million, $0.5 million and $0.6 million, respectively, during the nine months ended September 30, 2013 compared to the comparable period in 2012.

Cost of product revenue was $2.2 million during the nine months ended September 30, 2013, compared to $0.8 million for the comparable period in 2012. The $1.4 million increase is primarily attributable to an increase in associated product revenue recognized.

Research and development expenses were $14.4 million for the first nine months of 2013, compared to $16.0 million for the same period in 2012. The nine month decrease of $1.6 million is primarily the result of decreased employee compensation and benefit expenses of $1.0 million, reduced consulting fees of $0.3 million, and decreased depreciation expense of $0.3 million. Selling, general and administrative expenses were $9.7 million for the first nine months of 2013, as compared to $11.0 million for the comparable nine-month period in 2012. The decrease of $1.3 million is primarily the result of decreased employee compensation and benefit expenses of $0.7 million and a $0.4 million reduction in professional fees related to patent activities.The Company reported a net loss of $21.9 million, or $0.64 per share, for the nine months ended September 30, 2013 compared to net income of $13.1 million, or $0.38 per share, for the same period in 2012.

The Company's net cash used in operating activities during the nine months ended September 30, 2013 was $20.2 million, which represents a decrease in cash usage from $24.4 million for the comparable period in 2012. The $4.2 million decrease in net cash usage is primarily attributed to the Company's payment of $3.0 million to Telles in early 2012 to acquire the inventory from the ended Telles joint venture, and reduced operating expenses period-over-period. The Company currently expects that its cash and investments, together with funds expected to be received from existing government research grants and expected product sales, will be sufficient to meet its projected operating requirements into the third quarter of 2014. The Company will attempt to obtain additional funding through public or private financing, collaborative arrangements with strategic partners or through additional credit lines or other debt financing sources, in order to increase the funds available to support future operations.

Conference Call Information Metabolix management will host a conference call today at 4:30 p.m. (ET) to discuss the results of the third quarter. The Company also will provide an update on the business and answer questions from the investment community. A live webcast of the call with slides can be accessed through the Company's website at http://www.metabolix.com in the investor relations section. To participate in the call, dial toll-free 877-709-8155 or 201-689-8881 (international).

To listen to a telephonic replay of the conference call, dial toll-free 877-660-6853 or 201-612-7415 (international) and enter pass code 100574. The replay will be available beginning at 7:30 p.m. (ET) on Tuesday, November 5, 2013 and will last through 11:59 p.m. (ET) on Tuesday, November 19, 2013. In addition, the webcast will be archived on the Company's website in the investor relations section.

About MetabolixMetabolix, Inc. is an advanced biomaterials company that is well positioned to address growing market demand for sustainable solutions in the plastics, chemicals and energy industries. The Company is developing and commercializing a family of high-performance biopolymers targeted to the markets for film and bag applications, performance additives and functional biodegradation. Metabolix's biobased chemicals platform is focused on high-value segments and applications using its novel "FAST" recovery process. The Company also is developing a platform for co-producing plastics, chemicals and energy from crops. Metabolix has established an industry-leading intellectual property portfolio that, together with its knowledge of advanced industrial practice, provides a foundation for industry collaborations.

For more information, please visit www.metabolix.com.
(MBLX-E)

Safe Harbor for Forward-Looking Statements This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding expectations for establishing commercial PHA manufacturing; expected market demand for the Company's PHA products; expected future financial results and cash requirements; plans for obtaining additional funding; and expectations for future research and development and collaborations constitute forward-looking statements.  Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Metabolix's filings with the Securities and Exchange Commission, including its 10-K for the year ended December 31, 2012 filed on March 28, 2013. Metabolix assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

(FINANCIAL TABLES FOLLOW)

 METABOLIX, INC.CONDENSED CONSOLIDATED STATEMENT OF OPERATIONSUNAUDITED(in thousands, except share and per share data)Three Months EndedNine Months EndedSeptember 30,September 30,2013201220132012Revenue:Revenue from termination of ADM collaboration

$

-$

-$

-$

38,885Product revenue265701,876457Grant revenue5635761,8711,415Research and development revenue--618-License fee and royalty revenue 2728139162Total revenue8556744,50440,919Costs and expenses:Cost of product revenue4593162,212808Research and development expenses4,6434,93114,44615,982Selling, general, and administrative expenses2,9953,1709,72811,006Total costs and expenses8,0978,41726,38627,796Income (loss) from operations(7,242)(7,743)(21,882)13,123Other income (expense):Interest income, net102743102Other expense, net(19)(29)(40)(78)Total other income (expense), net(9)(2)324Net income (loss)

$

(7,251)$

(7,745)$

(21,879)$

13,147Net income (loss) per share:Basic

$

(0.21)$

(0.23)$

(0.64)$

0.38Diluted

$

(0.21)$

(0.23)$

(0.64)$

0.38Number of shares used in per share calculations:Basic34,516,05134,243,79234,435,12934,188,146Diluted34,516,05134,243,79234,435,12934,270,455 METABOLIX, INC.CONDENSED CONSOLIDATED BALANCE SHEETUNAUDITED(in thousands)September 30,December 31,20132012AssetsCash, cash equivalents and short-term investments$

25,748$

43,773Inventory3,4003,204Other current assets1,7951,978Restricted cash619594Property and equipment, net8911,358Long-term investments-2,508Other assets5095Total assets$

32,503$

53,510Liabilities and Stockholders' EquityAccounts payable and accrued liabilities$

3,612$

4,752Short-term deferred revenue4501,067Current portion of deferred rent97165Other current liabilities141-Other long-term liabilities-186Total liabilities4,3006,170Total stockholders' equity28,20347,340Total liabilities and stockholders' equity$

32,503$

53,510 METABOLIX, INC.CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWSUNAUDITED(in thousands)Nine Months Ended September 30,20132012Cash flows from operating activitiesNet loss$

(21,879)$

13,147Adjustments to reconcile net loss to cash used in operating activities:Depreciation 7371,026Charge for 401(k) company common stock match356350Stock-based compensation2,4412,935Inventory impairment317-Changes in operating assets and liabilities:Inventory(513)(3,028)Deferred revenue(617)(37,900)Other operating assets and liabilities(1,056)(954)Net cash used in operating activities(20,214)(24,424)Cash flows from investing activitiesPurchase of property and equipment(281)(397)Proceeds from sale of equipment-12Change in restricted cash(25)28Purchase of investments(15,621)(56,428)Proceeds from sale and maturity of short-term investments30,44777,320Net cash provided by investing activities14,52020,535Cash flows from financing activitiesProceeds from options exercised1419Net cash provided by financing activities 1419Effect of exchange rate changes on cash and cash equivalents(20)(2)Net decrease in cash and cash equivalents(5,700)(3,872)Cash and cash equivalents at beginning of period14,57221,277Cash and cash equivalents at end of period$

8,872$

17,405 


'/>"/>
SOURCE Metabolix
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Metabolix Announces Second Quarter 2013 Financial Results
2. Metabolix Announces Promotion of Johan van Walsem to Chief Operating Officer
3. Metabolix Executives to Present at Leading Industry Conferences
4. Discovery Labs Announces Completion of $50 Million Public Offering
5. Life Technologies Announces Third Quarter 2013 Results
6. Colby Pharmaceutical Company Announces Dramatic Results: Novel Technology Increases Influenza Vaccine Protection for Elderly Rhesus Monkeys
7. TVM Capital Group Announces Two-pronged Global Investment Strategy with Renewed MENA Focus
8. Veracyte, Inc. Announces Closing of Initial Public Offering
9. Spherix Announces Private Placement as the Company Continues to Execute its Patent Monetization Program - Spherix accepts $2.0 Million from Investors
10. Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I/IIa Clinical Trial for Treatment of Knee Osteoarthritis (KOA)
11. SureClinical Announces SurePortal™, First 100% Paperless eTMF Investigator Portal for Automated Document Completion Across Mobile, Web
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche ... with peritoneal or pleural mesothelioma. Their findings are the subject of a new article ... Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... pleased to announce the launch of their brand, UP4™ Probiotics, into Target stores ... 35 years, is proud to add Target to its list of well-respected retailers. ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):